PMID- 34719161
OWN - NLM
STAT- MEDLINE
DCOM- 20211102
LR  - 20220531
IS  - 0529-5807 (Print)
IS  - 0529-5807 (Linking)
VI  - 50
IP  - 11
DP  - 2021 Nov 8
TI  - [Clinicopathological characteristics of SMARCB1(INI1)-deficient sinonasal 
      carcinoma].
PG  - 1240-1245
LID - 10.3760/cma.j.cn112151-20210629-00469 [doi]
AB  - Objective: To investigate the clinicopathological characteristics, diagnosis, 
      differential diagnosis and prognostic factors of SMARCB1 (INI1)-deficient 
      sinonasal carcinoma (SDSC). Methods: Sixteen cases of SDSC diagnosed in the 
      Department of Pathology, Beijing Tongren Hospital from January 2016 to September 
      2020 were enrolled. Ninety-nine cases of small round cell malignant tumors of the 
      head and neck were selected as the control, including poorly-differentiated 
      squamous cell carcinoma (n=10), poorly-differentiated adenocarcinoma (n=5), 
      undifferentiated carcinoma (SNUC, n=4), NUT carcinoma (n=5), neuroendocrine 
      carcinoma (n=10), and other non-epithelial tumors [olfactory neuroblastoma 
      (n=10), rhabdomyosarcoma (n=10), NK/T-cell lymphoma (n=10), malignant melanoma 
      (n=10), Ewing's sarcoma/primitive neuroectodermal tumor (EWS/PNET, n=5)] and 
      non-keratinizing undifferentiated nasopharyngeal carcinoma (n=20). The clinical 
      and pathologic characteristics of SDSC, and immunohistochemical (IHC) expression 
      of broad-spectrum CKpan, CK7, CK8/18, CK5/6, p63, p40, p16, INI1, NUT and 
      neuroendocrine markers (Syn, CgA, CD56) were evaluated. In situ hybridization 
      (ISH) was used to detect EBER and fluorescence in situ hybridization (FISH) to 
      detect INI1 gene deletion. Results: The 16 cases of SDSC accounted for 1.3% (16/1 
      218) of all malignant sinonasal tumors in the author's unit during this time 
      period, and 2.4% (16/657) of all malignant epithelial tumors. Microscopically, 
      there was no clear squamous and adenomatous differentiation, but "rhabdoid-like" 
      cells, are often seen. All SDSC cases were positive for CKpan and CK8/18, 
      negative for INI1; Epstein-Barr virus was not detected by ISH; and INI1 gene 
      deletion was observed in all 11 SDSC patients with FISH. Twelve cases were 
      followed up for 3-47 months. One died of tumor-related diseases half a year after 
      diagnosis, and the remaining patients were alive with tumor, the longest survival 
      time was 47 months. Conclusion: SDSC should be differentiated from a variety of 
      poorly-differentiated tumors in the sinonasal area. Histologically, SDSC has no 
      clear differentiation, but the tumor cells are characteristically basal-like or 
      rhabdoid-like, with non-specific vacuoles, translucent or vacuolar nuclei, 
      prominent nucleoli and necrotic foci. They are negative for INI1 IHC staining, 
      and FISH demonstrates INI1 gene deletion. The clinical prognosis is still 
      unclear, further studies on its biologic behavior and treatment methods are 
      warranted.
FAU - Wang, J Y
AU  - Wang JY
AD  - Department of Pathology, Beijing Tongren Hospital, Capital Medical University, 
      Beijing Key Laboratory of Head and Neck Molecular Diagnostic Pathology, Beijing 
      100730, China.
FAU - Bai, Y P
AU  - Bai YP
AD  - Department of Pathology, Beijing Tongren Hospital, Capital Medical University, 
      Beijing Key Laboratory of Head and Neck Molecular Diagnostic Pathology, Beijing 
      100730, China.
FAU - Xing, L
AU  - Xing L
AD  - Department of Pathology, Beijing Tongren Hospital, Capital Medical University, 
      Beijing Key Laboratory of Head and Neck Molecular Diagnostic Pathology, Beijing 
      100730, China.
FAU - Piao, Y S
AU  - Piao YS
AD  - Department of Pathology, Beijing Tongren Hospital, Capital Medical University, 
      Beijing Key Laboratory of Head and Neck Molecular Diagnostic Pathology, Beijing 
      100730, China.
FAU - He, X J
AU  - He XJ
AD  - Department of Pathology, Beijing Tongren Hospital, Capital Medical University, 
      Beijing Key Laboratory of Head and Neck Molecular Diagnostic Pathology, Beijing 
      100730, China.
FAU - Yue, C L
AU  - Yue CL
AD  - Department of Pathology, Beijing Tongren Hospital, Capital Medical University, 
      Beijing Key Laboratory of Head and Neck Molecular Diagnostic Pathology, Beijing 
      100730, China.
FAU - Zhao, X L
AU  - Zhao XL
AD  - Department of Pathology, Beijing Tongren Hospital, Capital Medical University, 
      Beijing Key Laboratory of Head and Neck Molecular Diagnostic Pathology, Beijing 
      100730, China.
FAU - Liu, H G
AU  - Liu HG
AD  - Department of Pathology, Beijing Tongren Hospital, Capital Medical University, 
      Beijing Key Laboratory of Head and Neck Molecular Diagnostic Pathology, Beijing 
      100730, China.
LA  - chi
GR  - ZYLX201814/Beijing Municipal Administration of Hospitals Clinical Medicine 
      Development of Special Funding/
PT  - Journal Article
PL  - China
TA  - Zhonghua Bing Li Xue Za Zhi
JT  - Zhonghua bing li xue za zhi = Chinese journal of pathology
JID - 0005331
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (SMARCB1 Protein)
RN  - 0 (SMARCB1 protein, human)
SB  - IM
MH  - Biomarkers, Tumor/genetics
MH  - *Carcinoma, Squamous Cell/genetics
MH  - Humans
MH  - Immunohistochemistry
MH  - In Situ Hybridization, Fluorescence
MH  - *Paranasal Sinus Neoplasms/genetics
MH  - SMARCB1 Protein/genetics
EDAT- 2021/11/02 06:00
MHDA- 2021/11/03 06:00
CRDT- 2021/11/01 02:08
PHST- 2021/11/01 02:08 [entrez]
PHST- 2021/11/02 06:00 [pubmed]
PHST- 2021/11/03 06:00 [medline]
AID - 10.3760/cma.j.cn112151-20210629-00469 [doi]
PST - ppublish
SO  - Zhonghua Bing Li Xue Za Zhi. 2021 Nov 8;50(11):1240-1245. doi: 
      10.3760/cma.j.cn112151-20210629-00469.